A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Trial Profile

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Erlotinib
  • Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 06 Sep 2016 Toxicity and efficacy results (n=22) published in the Journal of Thoracic Oncology.
    • 12 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top